PARABO - Pain Evaluation in Radium-223 (Xofigo) Treated mCRPC Patients With Bone Metastases - a Non-interventional Study in Nuclear Medicine Centers

Trial Profile

PARABO - Pain Evaluation in Radium-223 (Xofigo) Treated mCRPC Patients With Bone Metastases - a Non-interventional Study in Nuclear Medicine Centers

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Bone metastases
  • Focus Therapeutic Use
  • Acronyms PARABO
  • Sponsors Bayer
  • Most Recent Events

    • 29 Sep 2017 Planned number of patients changed from 300 to 350.
    • 10 Jun 2017 Biomarkers information updated
    • 31 Mar 2017 Planned End Date changed from 1 Dec 2019 to 30 Sep 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top